• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肾细胞癌中的VEGF靶向治疗：活性药物与活性选择

VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.

作者信息

Rini Brian I

机构信息

Cleveland Clinic Foundation, 9500 Euclid Avenue/Desk R35, Cleveland, OH 44195, USA.

出版信息

Curr Oncol Rep. 2006 Mar;8(2):85-9. doi: 10.1007/s11912-006-0041-5.

DOI:10.1007/s11912-006-0041-5
PMID:16507216
Abstract

Several molecular pathways are implicated in renal cell carcinoma (RCC) pathogenesis, including von Hippel--Lindau (VHL) gene inactivation leading to vascular endothelial growth factor (VEGF) expression. Therapeutic targeting of VEGF and related pathways has been undertaken in metastatic RCC. Substantial clinical activity has been reported for multiple agents, leading to several clinical questions regarding the optimal use of these agents. The biology, clinical results, and future considerations regarding VEGF-targeted agents in RCC are presented in this article.

摘要

几种分子途径与肾细胞癌（RCC）的发病机制有关，包括导致血管内皮生长因子（VEGF）表达的von Hippel-Lindau（VHL）基因失活。转移性肾细胞癌已针对VEGF及相关途径进行了靶向治疗。已报道多种药物具有显著的临床活性，这引发了关于这些药物最佳使用方式的若干临床问题。本文介绍了肾细胞癌中VEGF靶向药物的生物学特性、临床结果及未来考量。

相似文献

1
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.肾细胞癌中的VEGF靶向治疗：活性药物与活性选择
Curr Oncol Rep. 2006 Mar;8(2):85-9. doi: 10.1007/s11912-006-0041-5.
2
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.希佩尔-林道基因状态与转移性透明细胞肾细胞癌对血管内皮生长因子靶向治疗的反应
J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.
3
Molecular biology of renal cell carcinoma.肾细胞癌的分子生物学
Clin Transl Oncol. 2006 Oct;8(10):706-10. doi: 10.1007/s12094-006-0116-7.
4
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.转移性肾细胞癌的血管内皮生长因子靶向治疗
Cancer. 2009 May 15;115(10 Suppl):2306-12. doi: 10.1002/cncr.24227.
5
Targeted therapy for metastatic renal cell carcinoma.转移性肾细胞癌的靶向治疗
J Clin Oncol. 2006 Dec 10;24(35):5601-8. doi: 10.1200/JCO.2006.08.5415.
6
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.转移性肾细胞癌患者通过序贯靶向治疗改善生存终点。
Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10.
7
Progress in the management of advanced renal cell carcinoma (RCC).晚期肾细胞癌（RCC）治疗的进展
Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. doi: 10.1055/s-0030-1247237. Epub 2010 Jan 21.
8
Signaling inhibitors in metastatic renal cell carcinoma.转移性肾细胞癌中的信号传导抑制剂
Cancer J. 2008 Sep-Oct;14(5):325-9. doi: 10.1097/PPO.0b013e3181867605.
9
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.舒尼替尼、索拉非尼及mTOR抑制剂在肾癌中的应用
J BUON. 2007 Sep;12 Suppl 1:S151-62.
10
Targeting von Hippel-Lindau pathway in renal cell carcinoma.靶向肾细胞癌中的希佩尔-林道通路
Clin Cancer Res. 2006 Dec 15;12(24):7215-20. doi: 10.1158/1078-0432.CCR-06-2254.

本文引用的文献

1
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.血管内皮生长因子通路在肿瘤生长和血管生成中的作用。
J Clin Oncol. 2005 Feb 10;23(5):1011-27. doi: 10.1200/JCO.2005.06.081. Epub 2004 Dec 7.
2
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.吉非替尼（易瑞沙，ZD1839）用于IV期及复发性肾细胞癌的II期试验。
Clin Cancer Res. 2004 Dec 1;10(23):7812-9. doi: 10.1158/1078-0432.CCR-04-0310.
3
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
BAY 43 - 9006具有广谱口服抗肿瘤活性，作用于参与肿瘤进展和血管生成的RAF/MEK/ERK信号通路及受体酪氨酸激酶。
Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443.
4
Bevacizumab for patients with metastatic renal cancer: an update.贝伐单抗用于转移性肾癌患者：最新进展
Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6367S-70S. doi: 10.1158/1078-0432.CCR-050006.
5
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.抑制癌症中的血管内皮生长因子（VEGF）信号传导会导致内皮窗孔丧失、肿瘤血管消退以及基底膜残影出现。
Am J Pathol. 2004 Jul;165(1):35-52. doi: 10.1016/S0002-9440(10)63273-7.
6
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.癌症与白血病B组90206研究：一项关于α干扰素或α干扰素联合抗血管内皮生长因子抗体（贝伐单抗）治疗转移性肾细胞癌的随机III期试验。
Clin Cancer Res. 2004 Apr 15;10(8):2584-6. doi: 10.1158/1078-0432.ccr-03-0605.
7
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.
Invest New Drugs. 2003 Aug;21(3):341-5. doi: 10.1023/a:1025472712456.
8
Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.缺氧诱导因子激活VHL（-/-）肾癌细胞中的转化生长因子-α/表皮生长因子受体生长刺激途径。
J Biol Chem. 2003 Nov 7;278(45):44966-74. doi: 10.1074/jbc.M305502200. Epub 2003 Aug 27.
9
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.一项关于抗血管内皮生长因子抗体贝伐单抗用于转移性肾癌的随机试验。
N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.
10
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.抗表皮生长因子受体抗体C225用于晚期肾细胞癌患者的II期试验。
Invest New Drugs. 2003 Feb;21(1):99-101. doi: 10.1023/a:1022928612511.